179 related articles for article (PubMed ID: 17239587)
1. 1,2,3-Thiadiazole substituted pyrazolones as potent KDR/VEGFR-2 kinase inhibitors.
Tripathy R; Ghose A; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Aimone LD; Herman JL; Mallamo JP
Bioorg Med Chem Lett; 2007 Mar; 17(6):1793-8. PubMed ID: 17239587
[TBL] [Abstract][Full Text] [Related]
2. Structure-guided identification of novel VEGFR-2 kinase inhibitors via solution phase parallel synthesis.
Tripathy R; Reiboldt A; Messina PA; Iqbal M; Singh J; Bacon ER; Angeles TS; Yang SX; Albom MS; Robinson C; Chang H; Ruggeri BA; Mallamo JP
Bioorg Med Chem Lett; 2006 Apr; 16(8):2158-62. PubMed ID: 16460933
[TBL] [Abstract][Full Text] [Related]
3. Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.
Tripathy R; McHugh RJ; Ghose AK; Ott GR; Angeles TS; Albom MS; Huang Z; Aimone LD; Cheng M; Dorsey BD
Bioorg Med Chem Lett; 2011 Dec; 21(24):7261-4. PubMed ID: 22061645
[TBL] [Abstract][Full Text] [Related]
4. Pharmacophore and docking-based combined in-silico study of KDR inhibitors.
Pasha FA; Muddassar M; Neaz MM; Cho SJ
J Mol Graph Model; 2009 Aug; 28(1):54-61. PubMed ID: 19447057
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
Wu Z; Fraley ME; Bilodeau MT; Kaufman ML; Tasber ES; Balitza AE; Hartman GD; Coll KE; Rickert K; Shipman J; Shi B; Sepp-Lorenzino L; Thomas KA
Bioorg Med Chem Lett; 2004 Feb; 14(4):909-12. PubMed ID: 15012992
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Liu L; Norman MH; Lee M; Xi N; Siegmund A; Boezio AA; Booker S; Choquette D; D'Angelo ND; Germain J; Yang K; Yang Y; Zhang Y; Bellon SF; Whittington DA; Harmange JC; Dominguez C; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1868-97. PubMed ID: 22320327
[TBL] [Abstract][Full Text] [Related]
7. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
[TBL] [Abstract][Full Text] [Related]
9. The development of novel inhibitors of tumor necrosis factor-alpha (TNF-alpha) production based on substituted [5,5]-bicyclic pyrazolones.
Laufersweiler MJ; Brugel TA; Clark MP; Golebiowski A; Bookland RG; Laughlin SK; Sabat MP; Townes JA; VanRens JC; De B; Hsieh LC; Heitmeyer SA; Juergens K; Brown KK; Mekel MJ; Walter RL; Janusz MJ
Bioorg Med Chem Lett; 2004 Aug; 14(16):4267-72. PubMed ID: 15261284
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design of novel class II c-Met inhibitors: 1. Identification of pyrazolone-based derivatives.
Norman MH; Liu L; Lee M; Xi N; Fellows I; D'Angelo ND; Dominguez C; Rex K; Bellon SF; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1858-67. PubMed ID: 22320343
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
12. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
[TBL] [Abstract][Full Text] [Related]
13. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase.
Bilodeau MT; Rodman LD; McGaughey GB; Coll KE; Koester TJ; Hoffman WF; Hungate RW; Kendall RL; McFall RC; Rickert KW; Rutledge RZ; Thomas KA
Bioorg Med Chem Lett; 2004 Jun; 14(11):2941-5. PubMed ID: 15125964
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling studies of vascular endothelial growth factor receptor tyrosine kinase inhibitors using QSAR and docking.
Du J; Lei B; Qin J; Liu H; Yao X
J Mol Graph Model; 2009 Jan; 27(5):642-54. PubMed ID: 19081278
[TBL] [Abstract][Full Text] [Related]
15. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).
Huang S; Li R; Connolly PJ; Emanuel S; Fuentes-Pesquera A; Adams M; Gruninger RH; Seraj J; Middleton SA; Davis JM; Moffat DF
Bioorg Med Chem Lett; 2007 Apr; 17(8):2179-83. PubMed ID: 17317182
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and SAR of 4-(3-hydroxyphenylamino)pyrrolo[2,1-f][1,2,4]triazine based VEGFR-2 kinase inhibitors.
Borzilleri RM; Cai ZW; Ellis C; Fargnoli J; Fura A; Gerhardt T; Goyal B; Hunt JT; Mortillo S; Qian L; Tokarski J; Vyas V; Wautlet B; Zheng X; Bhide RS
Bioorg Med Chem Lett; 2005 Mar; 15(5):1429-33. PubMed ID: 15713401
[TBL] [Abstract][Full Text] [Related]
18. Potent 2-[(pyrimidin-4-yl)amine}-1,3-thiazole-5-carbonitrile-based inhibitors of VEGFR-2 (KDR) kinase.
Sisko JT; Tucker TJ; Bilodeau MT; Buser CA; Ciecko PA; Coll KE; Fernandes C; Gibbs JB; Koester TJ; Kohl N; Lynch JJ; Mao X; McLoughlin D; Miller-Stein CM; Rodman LD; Rickert KW; Sepp-Lorenzino L; Shipman JM; Thomas KA; Wong BK; Hartman GD
Bioorg Med Chem Lett; 2006 Mar; 16(5):1146-50. PubMed ID: 16368234
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of indazole-based compounds as a new class of potent KDR/VEGFR-2 inhibitors.
Bauer D; Whittington DA; Coxon A; Bready J; Harriman SP; Patel VF; Polverino A; Harmange JC
Bioorg Med Chem Lett; 2008 Sep; 18(17):4844-8. PubMed ID: 18682324
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore modeling and in silico screening for new KDR kinase inhibitors.
Yu H; Wang Z; Zhang L; Zhang J; Huang Q
Bioorg Med Chem Lett; 2007 Apr; 17(8):2126-33. PubMed ID: 17306530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
